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Background: Vitamin E is a nutrient with both antioxidant and non-antioxidant activities and has been shown to
modulate the function of a number of cell types in vitro and in human studies. However studies have also shown
vitamin E to have detrimental interactions and therefore it is important to establish the extent to which this
nutrient influences metabolism. Metabolomics can potentially identify nutrient-metabolism interactions and
therefore the aim of this study was to use a non-targeted metabolomic approach to identify changes to the plasma
metabolome following vitamin E supplementation in humans.
Methods: A relatively homogenous healthy adult male population (n = 10) provided a fasting blood sample
immediately before and after a 4-week vitamin E supplementation regime (400 mg/d of RRR-α-tocopheryl acetate))
on top of their habitual diet. Plasma samples were analysed for vitamin E and clinical markers. Plasma underwent
non-targeted metabolite profiling using liquid chromatography/mass spectroscopy and data was processed using
multivariate statistical analysis.
Results: Plasma vitamin E concentrations were significantly increased following supplementation (p < 0.001). A
partial least squares-discriminant analysis (PLS-DA) model was able to discriminate between samples taken pre and
post vitamin E supplementation (goodness of fit R2Y = 0.82, predictive ability Q2 = 0.50). Variable influence on
projection and PLS-DA loadings highlighted a number of discriminating ions that were confirmed as discriminatory
through pairwise analysis. From database searches and comparison with standards these metabolites included a
number of lysophosphatidylcholine species (16:0, 18:0, 18:1, 18:2, 20:3 and 22:6) that were increased in intensity post
supplementation by varying degrees from 4% to 29% with the greatest changes found for lysoPC 22:6 and 20:3.
Conclusions: Although a small scale study, these results potentially indicate that vitamin E supplementation
influences phospholipid metabolism and induces lysoPC generation; a general pro-inflammatory response.
Moreover the study identifies novel areas of vitamin E interactions and highlights the potential of metabolomics for
elucidating interactions between nutrients and metabolic pathways in nutritional research.
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It is well established that nutrients interact with metabolic
pathways at various levels and have multiple targets. With
the increasing use of ‘-omic’ technologies in nutritional
research [1] it is now becoming possible to further explore
the influence of single nutrients or dietary change on
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distribution, and reproduction in any mediumVitamin E has been widely researched owing to its
antioxidant [2] and non-antioxidant functions [3] and its
potential as a cardioprotective agent. Vitamin E appears
to have wide ranging effects on cellular systems with the
ability to inhibit protein kinase C, activating diacylgly-
cerol kinase (decreasing diacylglycerol availability) and
protein phosphatase 2A [4], regulating specific gene
expression [5,6]; in this way vitamin E can influence a
number of biological functions and metabolism. Interest-
ingly, α-TTP knock out mice (model of vitamin E defi-
ciency) had lower glucose levels, improved glucose
tolerance and increased insulin excretion [7] indicating antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Vitamin E supplementation has been shown to influence
platelet [8] and mononuclear cell functions [8,9], and
reduce indices of oxidative stress and inflammation [10]
in humans. However vitamin E may also have potential
detrimental actions as high dose (>400 mg/d) supple-
mentation was found to increase mortality in a meta-
analysis [11] and high dose supplementation has been
proposed to potentially interfere with drug metabolism
[12]. As nutrients generally have multiple targets and
interactions, it is likely that vitamin E has alternate func-
tions and can further influence metabolic pathways.
Metabolomics offers the opportunity to investigate
global changes to metabolites in biological samples and
there is much interest in this technology for nutritional
studies [1,13]. Potential opportunities include a further
understanding of the interactions of whole diet or indi-
vidual nutrients on metabolic pathways, the metabolic
interactions between diet and disease, and developing
biomarkers for dietary exposure and/or disease [14,15].
Metabolomic technology has been applied to a number
of nutritional studies (reviewed in [1,16]), allowing inves-
tigators to compare the influence of dietary patterns on
metabolite profiles [17], monitor nutrient metabolism or
identify novel metabolic pathways influenced by the
nutrient [18]. Interestingly metabolomics has previously
been used in animal models to investigate vitamin E
metabolism. Following pregnane X receptor activation in
knockout mice there was an attenuation of α-tocopherol
metabolism but production of a novel γ-tocopherol
metabolite [19]. Novel vitamin E metabolites were also
found by Johnson et al. in human and mouse models by
LC/MS [20]. In a mouse model of neuronal ceroid lipo-
fuscinosis, vitamin E supplementation reversed meta-
bolic abnormalities associated with the phenotype [21].
In a rat liver model of vitamin E deficiency, the authors
found metabolic changes associated with amino acids,
glucose and purines that suggested shifts in energy
metabolism with deficiency [22]. In the only human
metabolic study involving vitamin E, metabolomics was
successfully used to determine ‘predictors of response’ to
vitamin E treatment in subjects with Non-Alcoholic
Steatohepatitis [23]. These studies demonstrate that
vitamin E can influence metabolic pathways and so it is
of interest to investigate other potential interactions in a
human supplementation study.
We have previously highlighted that metabolomics can
be used to provide insights into how vitamin E can influ-
ence the metabolome [16] and in the present study we
have expanded on these observations to identify subtle
but distinct changes to human plasma metabolome
following vitamin E supplementation, the main effects of
which include significant increases in the intensities of a
number of lysophospholipid species.Methods
Materials
All solvents were purchased from Fisher Scientific
(Loughborough, UK). Acetonitrile and methanol were
LC/MS grade, formic acid was laboratory reagent grade.
Water was purified using an Elga PureLab Ultra system
(Elga, High Wycombe, UK). Leucine encephalin and
lysophosphatidylcholine pure standards (analytical grade)
were purchased from Sigma Aldrich (Poole, UK). Gelatine
capsules containing 400 mg of natural (RRR) alpha-
tocopheryl acetate (purity 98.9%) in vitamin E-stripped
corn oil were purchased from Eurocaps Ltd. (Gwent, UK).
Human study
For this study 10 male subjects were recruited from
within the University of Surrey and surrounding area
through advertisement. Their average age and BMI were
32 ± 9 years and 24 ± 4 kg/m2 respectively. The subjects
were outwardly healthy, normolipidaemic (total choles-
terol 4.76 ± 1.3 mmol/L and triacylglycerols 0.95 ±
0.6 mmol/L) and were not taken any prescription medi-
cation or dietary supplements. The study was a one-way
supplementation trial with subjects taking a capsule con-
taining 400 mg of alpha-tocopheryl acetate every day for
4 weeks on top of their habitual diet (no dietary stand-
ardisation was performed). At the start and end of the
trial, subjects visited the clinical investigation unit at the
University of Surrey in a fasted state where they pro-
vided a blood sample (20 mL, EDTA). Under identical
conditions for each collection, plasma was harvested by
centrifugation, immediately aliquoted (0.5 mL), frozen
and stored at -80°C prior to analysis. The University of
Surrey Ethics Committee granted approval for this
study.
Sample preparation
For protein precipitation, 100 μl of freshly thawed
human plasma was vortex mixed with 400 μl of chilled
(-80°C) methanol for 1 min then left on ice for 10 min.
The mixture was then centrifuged at 13,000 rpm for
10 minutes and the supernatant transferred to autosam-
pler vials (Waters, Manchester, UK) for LC/MS analysis.
For metabolite identification, pure standards (1 ng/μL
injected) were dissolved in methanol and analysed under
the same conditions as for the plasma samples. Plasma
samples were also spiked with pure standards.
Liquid Chromatography Mass Spectrometry (LC/MS)
Chromatography was performed on a Waters Acquity
UPLC™ system (Waters, Manchester, UK) using an
Acquity BEH C18 column (1.7 μm 2.1 × 100 mm) for
sample separation following a 5 μL injection volume
using partial loop mode. The column oven was main-
tained at 40°C and the autosampler at 4°C. The mobile
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(B) acetonitrile with 0.1% formic acid. The gradient pro-
gram began with 100% (A) for 0.5 min, then proceeded
with a linear gradient to 100% (B) over 8.5 min, then
returned to initial conditions (100% A) and maintained
for 1 min. The total run time was 10 min with a flow
rate of 0.6 ml/min.
Mass Spectrometry was performed on a Waters
Micromass QToF Premier™ (Waters, Manchester, UK)
operating in both positive and negative ion electrospray
modes. The source temperature was set to 120°C, the
desolvation temperature was 450°C, with nebulisation
gas set to 800 L/hr. The collision energy was set at 4 eV.
The capillary and cone voltages were set at 3.1 kV and
38 V respectively in positive ionisation mode, and 2.9 kV
and 35 V respectively in negative ionisation mode. A
LockSpray™ interface was used to ensure mass accuracy.
For this leucine-enkephalin (556.2771 m/z in positive
ionisation mode) was infused at a concentration of 200
ρg/μL at a flow rate of 0.01 ml/min. Data was collected
in centroid mode over the range 100 to 1000 m/z with
an acquisition rate of 0.2 s, interscan delay of 0.02 s,
with dynamic range enhancement activated. MS/MS
experiments were performed by ramping the collision
energy from 10–50 V on selected masses of interest
while all other parameters remained the same. Each
sample was injected 6 times. The sample list was rando-
mised and also contained a quality control sample and a
metabolite test mix sample which were analysed follow-
ing every 20 injections in order to monitor retention
time and mass drift within the total analytical period.
Other analysis
Plasma vitamin E concentrations were analysed by
HPLC incorporating electrochemical detection as previ-
ously described [24]. Plasma total cholesterol, triacylgly-
cerols, glucose and nonesterified fatty acids were
measured using enzymatic test kits (Instrumentation La-
boratory, UK) on an automated clinical analyser
(ILab650, Instrumentation Laboratory, UK).
Data analysis
The acquired LC/MS data was analysed and visualised
using MassLynx and MarkerLynx (both Version 4.1,
Waters), using a noise elimination level set at 6 and 15
masses per retention time. Background ions from asso-
ciated blank injections were excluded from each sample.
The mass and retention time windows were 0.05 Da and
0.1 min respectively and signal drift was corrected auto-
matically by the software. The peak information was
then transferred to a multivariate analysis package
(SIMCA-P+,Ver 12, Umetrics AB, Sweden). Data were
initially analysed by Principal Component Analysis
(PCA) to identify any outliers. All variables were set toPareto scaling. A 2-component model was generated for
Partial Least Squares Discriminant Analysis (PLS-DA)
and the predictive ability (Q2) of the model assessed by
internal cross validation (seven-group venetian blind
cross-validation). A predictive set was established by
randomly removing 30% of the data to form a training
set and testing the predictive ability of the model against
the remaining ‘test’ data through averaging seven itera-
tions of the data. The model was able to correctly clas-
sify 72% of samples (in both groups) in a predictive set.
PLS-DA loadings and variable influence on projection
(VIP) plots were used to identify the most important dis-
criminatory species from the total list of features
detected. For the pairwise analysis of signal intensities,
Wilcoxon Matched Pairs tests were performed using
Prism (Ver 5, GraphPad Software Inc). A Bonferroni
correction, to take into account multiple comparisons,
was applied using the number of discriminating ions
from the VIP plot as the number of variables in the cal-
culation, giving an alpha level of 0.002. Only signals that
were significantly different with treatment (p < 0.05), or
a trend for significance (p < 0.1) following pair-wise
comparisons, underwent putative identification.
Results and discussion
In this study LC/MS based metabolomics has been
applied to plasma samples obtained pre and post vitamin
E supplementation. Metabolomics is being increasingly
used in nutritional studies [16], as it is of importance to
further understand how diet influences metabolic path-
ways and to develop biological markers of dietary expos-
ure [14]. Vitamin E supplementation has been shown to
have varied responses in a number of ex vivo and
in vitro studies and with the development of more
sophisticated research tools such as metabolomics, our
aim was to use this technology to identify any effects
of vitamin E supplementation on human metabolism.
Vitamin E plasma concentrations were relatively high at
baseline, suggesting the subjects were replete in vitamin
E, but values significantly increased from 31.53 ±
4.6 μmol/L before supplementation to 46.65 ±
5.16 μmol/L post supplementation (p < 0.001), which
represents a 1.5 fold increase in concentration. This is in
line with what is expected from similar vitamin E inter-
ventions [25] as it is known that due to hepatic regula-
tion plasma concentrations become saturated and
cannot be raised more than 2–3 fold [26]. There were
no changes to plasma concentrations of glucose, total
cholesterol and triacylglycerol following supplementa-
tion (data not shown).
Classification of samples
The LC/MS approach detected approximately 2500 ion
species in plasma samples, and there was no significant
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pre (2551 ± 176) and post (2556 ± 142) supplementation.
The data were firstly analysed by unsupervised Principal
Component Analysis (PCA) to check for overall data
quality (Figure 1a). We found no data points outside the
Hotelling confidence intervals and so no data points
were investigated further. PCA was unable to discrimin-
ate between sample groups (Figure 1a), however this is
not uncommon as PCA may not be sensitive enough to
discriminate between samples sets when there is large
variation and only modest differences between groups,
as commonly seen in nutritional studies [27].
To further explore the data a two-component PLS-DA
model was established (Figure 1b), and was able to dis-
criminate between treatment (model parameters; R2Y =
0.82, Q2 = 0.50), with samples post supplementation
clustering mainly to the left along the first latent variable
axis. To identify discriminatory species the data was
explored through a PLS-DA loadings plot and a VIP plot
of the first latent variable (Figure 2a and b respectively).
This generated a list of top discriminatory species above
a VIP score of 7.5. We then analysed single ion chroma-
tograms and associated molecular ions of the species in
the original data in order to check for adducts and re-
move false positive signals, and performed pairwise com-
parisons of ion intensities between sample class to
confirm differences between treatment groups. From this
analysis out of the approximately 2500 features initially
detected, only seven discriminatory signals remained for
further identification.
Identification of signals discriminatory for vitamin E
supplementation
To identify these discriminatory species, elemental com-
position analysis was performed using Masslynx toFigure 1 Multivariate analysis of data. (a) PCA and (b) PLS-DA scores pl
supplementation.obtain potential formulae. Masses were then entered
into metabolite databases (Human Metabolite Database,
www.hmdb.ca; METLIN, metlin.scripps.edu), and for-
mulae compared with possible elemental composition
taking into account potential adducts from molecular
ion analysis. To confirm identities pure compounds
were purchased when possible and analysed under iden-
tical conditions to that of the plasma samples, including
spiking of original samples. Molecular ion and fragmen-
tation patterns of the standards and the associated peak
in original samples, retention time and sample spiking
confirmed the assignments. An example of such an as-
signment strategy is shown in Figure 3 for the species at
7.78 min, 524.37 m/z in plasma. A positive ion mode
TIC of the region around the peak in a representative
plasma sample is shown in Figure 3a. A spectrum of the
peak at 7.78 min in positive mode (Figure 3b) revealed a
major signal at 524.372 m/z and in negative mode
(Figure 3c) at 568.36 and 508.34 m/z. The top match for
this signal from metabolite databases was found to be
the [M + H]+ adduct of lysophosphatidylcholine (C18:0).
MS/MS fragmentation patterns of the peak at 7.78 min
in positive mode (Figure 3d) revealed major signals at
184.07 and 104.10 m/z characteristic of the phospho-
choline moiety [28] and in negative mode (Figure 3e)
at 283.25 m/z characteristic of the [M-H]- adduct of
stearic acid. A comparison of this analysis with that of
a pure standard of lysophosphatidylcholine (C18:0)
(Figure 3f-j) revealed identical mass spectroscopy be-
haviour. Using the same approach, six lysophosphati-
dylcholine (LysoPC) species were assigned (Table 1)
that were increased in intensity post supplementation
(pairwise analysis, Figure. 4). Similar assignment strat-
egies were used for the confirmation of LysoPC in pre-
vious studies [29,30].ot showing samples pre (black square) and post (○) vitamin E
Figure 2 Multivariate analysis of data. (a) PLS-DA loadings plot of first two latent variables explaining separation in Figure 1b, and (b)
associated VIP plot of the first component highlighting discriminatory species.
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supplementation remain to be assigned as no matches
were found on metabolite databases. As vitamin E meta-
bolites appear in the plasma and urine following supple-
mentation [31] it may have been expected to find such
metabolites as discriminatory species in the current
study. The α-tocopherol metabolites α-carboxyethyl
hydroxychroman (α-CEHC) and its glucuronide deriva-
tive were found to be discriminating in a metabolomic
investigation in mice following activation of the preg-
nane X nuclear receptor [19]. However, molecular ions
of these species and their potential adducts were not
found in the current study, presumably a consequence
of the protein precipitation technique used.
Lysophophatidylcholine species are significantly
increased in response to vitamin E supplementation
The intensity of lysoPC species were increased varyingly;
22:6 (29%), 20:3 (21%), 18:0 (8%), 18:1 (7.5%), 18:2
(4.5%), and 16:0 (4%). LysoPC are products of phospho-
lipid metabolism formed predominantly through the ac-
tion of phospholipase A2 (PLA2) activity on biological
membranes, but also through Lecithin Cholesterol Acyl
Transferase (LCAT) activity between lipoproteins, and
during the oxidative modification of LDL [32]. When
LysoPC are formed there is a loss of a fatty acid mol-
ecule and so one might expect levels of nonesterified
fatty acids (NEFA) to increase in the plasma. We mea-
sured NEFA in pre and post samples and found NEFA
to be increased non-significantly following vitamin E
supplementation (0.189 ± 0.08 mmol/L in pre vs 0.202 ±
0.11 mmol/L in post). LysoPC have specific actions andare not simply a consequence of phospholipid metabol-
ism. LysoPC have pro-inflammatory activity, having the
ability to activate a variety of cell lines and this activa-
tion has been shown to be dependent on the acyl chain
length, with saturated species being the most effective
[33]. LysoPC are mediators of endothelial function [32],
capable of inducing endothelial dysfunction, platelet ac-
tivation [34], and migration of smooth muscle cells [35].
Some of these lysoPC actions appear to be mediated
through signal-regulated kinases [34], the release of
growth factors [35] and through binding to specific recep-
tors [32]. A release of lysoPC following vitamin E sup-
plementation would suggest a general pro-inflammatory
response, however vitamin E is thought to have anti-
inflammatory properties. Vitamin E has been shown to
attenuate the pro-inflammatory action of lysoPC in vari-
ous cell culture studies [34-36]. For example, a recent
study in high cardiovascular risk subjects demonstrated
an overall anti-inflammatory effect following long-term
vitamin E supplementation [10]. Opposing roles for
vitamin E can occur; the simultaneous potentiation of
PLA2 activity but inhibition of COX activity favoured
production of vasodilator prostanoids in endothelial
cells [37], and this may provide an overall beneficial ef-
fect in certain tissues and provide an explanation for
these contradictory findings.
It is interesting to note that impaired vitamin E regula-
tion appears to play a role in glucose control through
unknown mechanisms [7]. The finding that lysoPC are
involved in both adipocyte glucose uptake [38] and
glucose-dependent insulin secretion [39], and that lyso-
PC have been shown to be potential biomarkers of type
Figure 3 Mass spectroscopy of the peak at 7.78 min in a representative plasma sample (left panels (a)-(e)) and a pure standard of
lysophosphatidylcholine (C18:0) (right panels (f)-(j)). Panels (a) & (f) show a TIC of the region 6.3-8 mins. A spectrum of the peak at 7.78 min
is shown in panels (b) & (g) and panels (c) & (h) in positive and negative ion modes respectively. MS/MS spectrums of the same peak are shown
in panels (d) & (i) and (e) & (j) for positive and negative ion modes respectively.
Table 1 Major discriminatory species identified from the
PLS-DA loadings and VIP plot
VIP m/z [M + H]+ RT (min) P value* Assignment
18.02 524.371 7.78 0.037 LysoPC (18:0)
17.93 520.340 6.60 0.052 LysoPC (18:2)
16.02 496.339 6.93 0.085 LysoPC (16:0)
15.67 522.355 7.11 0.045 LysoPC (18:1)
13.32 546.356 6.88 0.018 LysoPC (20:3)
12.73 568.340 6.56 0.023 LysoPC (22:6)
9.59 235.181 2.61 0.012 NA
* from pairwise comparisons pre vs post, with an adjusted Bonferroni p value
(<0.002) no significance remained. NA, no assignment from metabolite
databases. All signals were increased in intensity post vitamin E
supplementation.
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and warrants further study.
Potential mechanisms of raised lysophosphatidylcholines
There are a number of potential mechanisms by which
vitamin E supplementation could increase levels of
lysoPC. Vitamin E has been shown to influence gene
expression of a number of systems and modulate the
activities of a number of enzymes involved in signal
transduction, including PLA2 [41]. Depending on the
model used vitamin E treatment has been shown to acti-
vate [37,42,43], inhibit [44-46] or have no effect [47] on
PLA2 activity, but the weight of evidence overall is
suggestive of an increase in PLA2 activity following vita-
min E exposure in cell/animal models. Because of the
difference in models used and lack of human data it is
not possible to relate PLA2 activity with vitamin E levels.
Vitamin E can form complexes with lysoPC which help
Figure 4 Increase in intensity of various lysophosphatidylcholine species post vitamin E supplementation. Data shown as mean ± SEM
signal intensity in samples taken pre (open boxes) and post (closed boxes) supplementation.
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is thought to stabilise membranes through its interaction
with phospholipids and other membrane components,
there is evidence that it can also destabilise [48]. An
increase in vitamin E content of biological membranes,
following supplementation, may potentially disrupt the
membrane causing displacement of membrane phospho-
lipids, which are metabolised releasing lysoPC. However
it is not known if a 1.5 fold increase in vitamin E content
(as found in the current study) could have these effects
on biological membranes. Alternatively the result may
not necessarily be specific to vitamin E but could be
representative of an acute phase response to the inter-
vention, or a similar phenomenon, as other studies have
found lysoPC to be discriminating species. For example,
a metabolomic study found a number of lysoPC species
increased during an oral glucose tolerance test [18].
LysoPC have also been associated with a number of
disease states and found to be increased in subjects with
hepatitis B-induced deterioration of liver function
[29], rheumatoid arthritis [49], type 2 diabetes [50]
and obesity [51], whereas lysoPC were significantly
decreased in subjects with colorectal cancer [52], and
in sepsis patients [53]. Therefore, as lysoPC appear
to be influenced by a number of physiological condi-
tions further work is necessary to elucidate the
mechanism of this effect and the identification of
other species influenced by vitamin E supplementa-
tion. It would be of interest to pursue and validate
these observations in a more comprehensive study of
vitamin E supplementation.Conclusions
Overall the data in this study suggest that vitamin E
supplementation influences phospholipid metabolism,
increasing the intensity of a variety of lysophosphatidyl-
choline species in plasma in the order 22:6 > 20:3> >
18:0 ~ 18:1 > 18:2 ~ 16:0. This is one of only a few reports
using metabolomics to investigate single nutrient interac-
tions in a human intervention study and highlights the po-
tential of metabolomic technology in nutrition research in
defining alternative functions for nutrients and elucidating
how nutrients interact with metabolic pathways, in this
case vitamin E.
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